Celecoxib to prevent restenosis - results from the COREA-TAXUS trial

Author: Doggrell, Sheila A

Source: Expert Opinion on Pharmacotherapy, Volume 9, Number 2, February 2008 , pp. 339-341(3)

Buy & download fulltext article:

Price: $99.00 plus tax (Refund Policy)

Abstract:

Celecoxib inhibits Akt, which is stimulated during restenosis. Cell and animal studies showed that celecoxib inhibited Akt stimulation and restenosis. Recently, the COREA-TAXUS (Effect of Celecoxib on Restenosis after Coronary Angioplasty with Taxus stent) trial was performed in subjects with angina or a positive-stress test receiving paclitaxel-eluting stents. The primary end point at 6 months was the in-stent, late luminal loss, which was 0.49 mm in the celecoxib-treated group; less than the 0.75 mm in the group not treated with celecoxib. The rate of revascularisation of the target lesion was lower in celecoxib-treated subjects (5%) than in the untreated subjects (15%). In conclusion, this is an excellent demonstration of translating a mechanism of action of a drug into a clinical use.

Keywords: Akt; celecoxib; clinical trial; coronary artery disease; restenosis; stent

Document Type: Research article

DOI: http://dx.doi.org/10.1517/14656566.9.2.339

Publication date: 2008-02-01

More about this publication?